Clinical Trials Browser

Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck × cemiplimab × 90 days × Clear all

NCT03565783 2026-02-25

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Phase 2 Active not recruiting

DermatologicHead & Neck

Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck